Raymond James assumed coverage on shares of Regenxbio (NASDAQ:RGNX) in a research note published on Thursday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating on the biotechnology company’s stock.

Other analysts have also recently issued reports about the company. ValuEngine raised Regenxbio from a buy rating to a strong-buy rating in a research report on Tuesday, March 5th. BidaskClub raised Regenxbio from a sell rating to a hold rating in a research report on Wednesday, March 6th. Evercore ISI raised Regenxbio from an in-line rating to an outperform rating and set a $51.25 target price for the company in a research report on Monday, February 25th. Zacks Investment Research raised Regenxbio from a hold rating to a buy rating and set a $52.00 target price for the company in a research report on Friday, February 22nd. Finally, TheStreet cut Regenxbio from a c rating to a d+ rating in a research report on Thursday, May 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock has an average rating of Hold and an average target price of $80.91.

NASDAQ:RGNX opened at $48.27 on Thursday. Regenxbio has a 1 year low of $38.56 and a 1 year high of $85.10. The company has a current ratio of 14.21, a quick ratio of 14.21 and a debt-to-equity ratio of 0.01.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.04). The business had revenue of $0.88 million for the quarter. Regenxbio had a negative return on equity of 9.90% and a negative net margin of 41.99%. As a group, equities research analysts expect that Regenxbio will post -2.79 EPS for the current fiscal year.

In related news, CEO Kenneth T. Mills sold 15,000 shares of the company’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $58.53, for a total value of $877,950.00. Following the completion of the sale, the chief executive officer now directly owns 261,000 shares of the company’s stock, valued at approximately $15,276,330. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Vittal Vasista sold 10,000 shares of the company’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $60.75, for a total value of $607,500.00. Following the completion of the sale, the chief financial officer now directly owns 230,915 shares of the company’s stock, valued at $14,028,086.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 80,000 shares of company stock valued at $4,158,370. Insiders own 13.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Berman Capital Advisors LLC acquired a new stake in Regenxbio during the 4th quarter worth approximately $33,000. Mckinley Capital Management LLC Delaware lifted its position in Regenxbio by 51.8% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 303 shares during the period. Financial Gravity Wealth Inc. acquired a new stake in Regenxbio during the 1st quarter worth approximately $55,000. PNC Financial Services Group Inc. lifted its position in Regenxbio by 568.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,190 shares of the biotechnology company’s stock worth $68,000 after acquiring an additional 1,012 shares during the period. Finally, NumerixS Investment Technologies Inc acquired a new stake in Regenxbio during the 4th quarter worth approximately $50,000. 81.67% of the stock is owned by hedge funds and other institutional investors.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: Portfolio Manager

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.